CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer.

Por: Guerrero-Zotano Á, Belli S, Zielinski C, Gil-Gil M, Fernandez-Serra A, Ruiz-Borrego M, Ciruelos Gil EM, Pascual J, Muñoz-Mateu M, Bermejo B, Margeli Vila M, Antón A, Murillo L, Nissenbaum B, Liu Y, Herranz J, Fernández-García D, Caballero R, López-Guerrero JA, Bianco R, Formisano L, Turner N and Martín M

---

Publicada: 14 abr 2023

---

---

Filiaciones:
Guerrero-Zotano Á:
 Medical Oncology, Instituto Valenciano de Oncología, Valencia, Spain

 GEICAM Spanish Breast Cancer Group, Madrid, Spain

Belli S:
 Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy

Zielinski C:
 Medical Oncology, Central European Cancer Center, Wiener Privatklinik Hospital, Vienna, Austria

 CECOG Central European Cooperative Oncology Group, Vienna, Austria

Gil-Gil M:
 GEICAM Spanish Breast Cancer Group, Madrid, Spain

 Institut Català d'Oncologia (ICO), Barcelona, Spain

 IDIBELL, L'Hospitalet, Barcelona, Spain

Fernandez-Serra A:
 Laboratory of Molecular Biology, Fundación Instituto Valenciano de Oncología, Valencia, Spain

Ruiz-Borrego M:
 GEICAM Spanish Breast Cancer Group, Madrid, Spain

 Medical Oncology, Hospital Universitario Virgen del Rocio, Sevilla, Spain

Ciruelos Gil EM:
 GEICAM Spanish Breast Cancer Group, Madrid, Spain

 Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain

 Medical Oncology, HM Hospitales Madrid, Madrid, Spain

 SOLTI Group on Breast Cancer Research, Barcelona, Spain

Pascual J:
 GEICAM Spanish Breast Cancer Group, Madrid, Spain

 Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, Málaga, Spain

 Institute of Cancer Research and Royal Marsden, London, United Kingdom

 Oncology Biomedical Research National Network (CIBERONC-ISCIII), Madrid, Spain

Muñoz-Mateu M:
 GEICAM Spanish Breast Cancer Group, Madrid, Spain

 Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain

 Translational Genomics and Targeted Therapeutics in Solid Tumors (IDIBAPS), Barcelona, Spain

Bermejo B:
 GEICAM Spanish Breast Cancer Group, Madrid, Spain

 Oncology Biomedical Research National Network (CIBERONC-ISCIII), Madrid, Spain

 Medical Oncology, Hospital Clínico Universitario de Valencia, Medicine Department, Universidad Medicina Valencia, Valencia, Spain

 Biomedical Research Institute INCLIVA, Valencia, Spain

Margeli Vila M:
 GEICAM Spanish Breast Cancer Group, Madrid, Spain

 B-ARGO Group, Catalan Institute of Oncology- Badalona, Hospital Universitari Germans Trias i Pujol, Badalona, Spain

Antón A:
 GEICAM Spanish Breast Cancer Group, Madrid, Spain

 Oncology Biomedical Research National Network (CIBERONC-ISCIII), Madrid, Spain

 Medical Oncology, Hospital Universitario Miguel Servet, Instituto de Investigación Sanitaria Aragón, Zaragoza, Spain

Murillo L:
 GEICAM Spanish Breast Cancer Group, Madrid, Spain

 Medical Oncology, Hospital Clínico de Zaragoza Lozano Blesa, Zaragoza, Spain

Nissenbaum B:
 Meir Medical Center, Kfar Saba, Israel

Liu Y:
 Pfizer, La Jolla, California

Herranz J:
 GEICAM Spanish Breast Cancer Group, Madrid, Spain

Fernández-García D:
 GEICAM Spanish Breast Cancer Group, Madrid, Spain

Caballero R:
 GEICAM Spanish Breast Cancer Group, Madrid, Spain

:
 Laboratory of Molecular Biology, Fundación Instituto Valenciano de Oncología, Valencia, Spain

 IVO-CIPF Joint Research Unit of Cancer, Príncipe Felipe Research Center (CIPF), Valencia, Spain

 Department of Pathology, School of Medicine, Catholic University of Valencia "San Vicente Mártir", Valencia, Spain

Bianco R:
 Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy

Formisano L:
 Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy

Turner N:
 Institute of Cancer Research and Royal Marsden, London, United Kingdom

Martín M:
 GEICAM Spanish Breast Cancer Group, Madrid, Spain

 Oncology Biomedical Research National Network (CIBERONC-ISCIII), Madrid, Spain

 Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Medicine Department, Universidad Complutense, Madrid, Spain